Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials

Diabetes Care

Volumn 35, Issue 12, 2012, Pages 2706-2717

  Santschi, Valérie ^a,b   Colosimo, April L ^a   Chiolero, Arnaud ^a,b   Burnand, Bernard ^b   Paradis, Gilles ^a,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ARTICLE; BEHAVIOR CHANGE; BEHAVIOR THERAPY; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES EDUCATION; DIABETES MELLITUS; DIET SUPPLEMENTATION; HUMAN; HYPERTENSION; INTERDISCIPLINARY COMMUNICATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE PRACTITIONER; OUTCOME ASSESSMENT; OUTPATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; PHYSICIAN; PHYSIOTHERAPIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; PHARMACISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84869754781     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0369     Document Type: Article

References (39)

1. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
4. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119:1728-1735
5. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29:531-537 (Pubitemid 44115349)
6. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-723 (Pubitemid 41071193)
7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342 (Pubitemid 38101606)
8. McLean DL, McAlister FA, Johnson JA, et al.; SCRIP-HTN Investigators. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med 2008; 168:2355-2361
9. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care 2010;48:923-933
10. Fera T, Bluml BM, Ellis WM. Diabetes Ten City Challenge: final economic and clinical results. J Am Pharm Assoc (2003) 2009;49:383-391
11. Santschi V, Rodondi N, Bugnon O, Burnier M. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med 2008;19:427-434
12. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-1155 (Pubitemid 34522403)
13. Villeneuve J, Genest J, Blais L, et al. A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ 2010;182:447-455
14. Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med 1998;13:740-745 (Pubitemid 28523563)
15. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171:1441-1453
16. Collins C, Limone BL, Scholle JM, Coleman CI. Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Res Clin Pract 2011;92:145-152
17. Evans CD, Watson E, Eurich DT, et al. Diabetes and cardiovascular disease interventions by community pharmacists: a systematic review. Ann Pharmacother 2011;45:615-628
18. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007; 41:1569-1582 (Pubitemid 47479786)
19. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 2008;28:421-436 (Pubitemid 351466454)
20. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100
21. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med 2008;168:687-694 (Pubitemid 351563951)
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org
23. Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy followup program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65-72 (Pubitemid 44510949)
24. Kraemer DF, Kradjan WA, Bianco TM, Low JA. A randomized study to assess the impact of pharmacist counseling of employer-based health plan beneficiaries with diabetes: the EMPOWER study. J Pharm Pract 2012;25:169-179
25. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2009;67:547-557
26. Chan CW, Siu SC, Wong CK, Lee VW. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther 2012;17:57-64
27. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist's input on glycaemic control and cardiovascular risks in Muslim diabetes. Prim Care Diabetes 2008;2:31-37
28. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc (2003) 2009;49:164-170
29. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005;118:276-284 (Pubitemid 40312639)
30. Sriram S, Chack LE, Ramasamy R, Ghasemi A, Ravi TK, Sabzghabaee AM. Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. J Res Med Sci 2011;16(Suppl 1.):S412-S418
31. Clifford RM, Davis WA, Batty KT, Davis TM; Fremantle Diabetes Study. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2005;28: 771-776 (Pubitemid 40434471)
32. Edelman D, Fredrickson SK, Melnyk SD, et al. Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial. Ann Intern Med 2010;152:689-696
33. Pape GA, Hunt JS, Butler KL, et al. Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial. Arch Intern Med 2011;171:1480-1486
34. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm 2006;63:2116-2122 (Pubitemid 44757783)
35. Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2011; 34:20-26
36. Taveira TH, Friedmann PD, Cohen LB, et al. Pharmacist-led group medical appointment model in type 2 diabetes. Diabetes Educ 2010;36:109-117
37. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care 2009;32(Suppl. 2):S429-S431
38. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 2008;87:801-809 (Pubitemid 351549222)
39. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:186-194